Rights issue 2026
Klaria carries out a rights issue of up to approximately SEK 147.6 million to strengthen its financial position ahead of an exciting commercial phase.
Klaria's licensing partner CNX Therapeutics is expected to launch the company's market-approved product Sumatriptan Alginate Film in Europe in the near future, and together with BDO, strategic alternatives (including for the US market) are being evaluated to maximize shareholder value.
Read more on the issue page (opens in new tab)
Documents
- Klaria Pharma Prospectus 2026 (opens in a new tab)
- Proposal issue of units with conditions (opens in a new tab)
- Proposal for issue authorization (opens in a new tab)
- Proposal amendment of the Articles of Association and new Articles of Association, without amendment marks (opens in a new tab)
- Proposal for amendment of the Articles of Association and new Articles of Association, with amendments (opens in a new tab)
- The Board's 13:6 and 14:8 report and the auditor's statement (opens in a new tab)
- The Board's 13:7 report and the auditor's statement (opens in a new tab)
- Auditor's statement on the Board of Directors' statement (opens in a new tab)
- Auditor's statement on the Board of Directors' statement on set-off (opens in a new tab)
- Amendment of Articles of Association (opens in a new tab)
- Minutes from the Extraordinary General Meeting (opens in a new tab)
